Androgen regulation of micro‐RNAs in prostate cancer

Androgens play a critical role in the growth of both androgen dependent and castration‐resistant prostate cancer (CRPC). Only a few micro‐RNAs (miRNAs) have been suggested to be androgen regulated. We aim to identify androgen regulated miRNAs.

[1]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[2]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[4]  W. E. Gye,et al.  CANCER RESEARCH , 1923, British medical journal.

[5]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[6]  Y. Akao,et al.  MicroRNA-141 and -200a Are Involved in Bone Morphogenetic Protein-2-induced Mouse Pre-osteoblast Differentiation by Targeting Distal-less Homeobox 5 , 2009, The Journal of Biological Chemistry.

[7]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[8]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[9]  C. Heinlein,et al.  The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. , 2002, Molecular endocrinology.

[10]  Holger Sültmann,et al.  Circulating miRNAs are correlated with tumor progression in prostate cancer , 2011, International journal of cancer.

[11]  G. Jenster,et al.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.

[12]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Isaacs,et al.  Androgen receptor outwits prostate cancer drugs , 2004, Nature Medicine.

[14]  A. DeMarzo,et al.  Cell‐autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells , 2010, The Prostate.

[15]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[16]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[17]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[18]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[19]  G. Jenster,et al.  Evolution of the androgen receptor pathway during progression of prostate cancer. , 2006, Cancer research.

[20]  Myles Brown,et al.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. , 2009, Cancer research.

[21]  Arndt Hartmann,et al.  The MicroRNA Profile of Prostate Carcinoma Obtained by Deep Sequencing , 2010, Molecular Cancer Research.

[22]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[23]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[24]  T. Golub,et al.  Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.

[25]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[26]  Aimee L Jackson,et al.  Myc-regulated microRNAs attenuate embryonic stem cell differentiation , 2009, The EMBO journal.

[27]  J. Stanford,et al.  Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. , 2009, Cancer research.

[28]  Christopher P Evans,et al.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.

[29]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[30]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[31]  M. Zhou,et al.  microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. , 2010, Carcinogenesis.

[32]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[33]  G. Jenster,et al.  The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. , 2006, European urology.

[34]  K. Waltering,et al.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.

[35]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[36]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[37]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[38]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[39]  Rainer Breitling,et al.  RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis , 2006, Bioinform..

[40]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[41]  O. Kent,et al.  Functional integration of microRNAs into oncogenic and tumor suppressor pathways , 2008, Cell cycle.

[42]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[43]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[44]  W. V. van Weerden,et al.  Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.

[45]  N. Colburn,et al.  MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene , 2008, Oncogene.

[46]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[47]  M. Rubin,et al.  Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. , 2009, Cancer research.

[48]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.